AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins

If you look at people with or without... T2D [type 2 diabetes], SGLT-2 inhibitors have been shown to decrease the risk of hospitalization and death for heart failure patients with reduced ejection fraction and improve basically all cardiovascular outcomes in patients with heart failure who have preserved EF.

How do we manage the problem of type 2 diabetes? ... You can manage it by reducing glucose. You can manage it by increasing insulin sensitivity. You can manage it by increasing insulin itself.

People are excited about metformin... because the belief is that it's doing something beyond regulating blood sugar. And I think to a lesser extent, in the public's eye, but probably to a greater extent in the scientific eye, the excitement is the same for SGLT-2 ihibitors.

When patients have heart failure with or without reduction in EF [ejection fraction], outcomes are better if they're taking SGLT-2 inhibitors, even if they are not patients with type 2 diabetes.